Q4 2017 EPS Estimates for Integra LifeSciences Holdings Corporation (IART) Lifted by Northcoast Research

Integra LifeSciences Holdings Corporation (NASDAQ:IART) – Northcoast Research increased their Q4 2017 earnings per share (EPS) estimates for Integra LifeSciences Holdings Corporation in a research report issued on Monday. Northcoast Research analyst D. Keiser now anticipates that the life sciences company will post earnings of $0.61 per share for the quarter, up from their previous forecast of $0.58. Northcoast Research also issued estimates for Integra LifeSciences Holdings Corporation’s Q1 2018 earnings at $0.45 EPS, Q2 2018 earnings at $0.53 EPS and Q4 2018 earnings at $0.67 EPS.

IART has been the topic of a number of other reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 price target on shares of Integra LifeSciences Holdings Corporation in a report on Monday, July 10th. ValuEngine downgraded Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. Jefferies Group LLC raised their target price on Integra LifeSciences Holdings Corporation from $50.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, April 28th. Oppenheimer Holdings, Inc. set a $54.00 target price on Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a research report on Monday, May 15th. Finally, Zacks Investment Research raised Integra LifeSciences Holdings Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, July 27th. Five analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $52.63.

ILLEGAL ACTIVITY NOTICE: This story was originally published by BNB Daily and is the sole property of of BNB Daily. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.baseball-news-blog.com/2017/08/19/q4-2017-eps-estimates-for-integra-lifesciences-holdings-corporation-iart-lifted-by-northcoast-research-updated-updated.html.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded down 1.47% on Tuesday, reaching $48.93. The company’s stock had a trading volume of 173,532 shares. Integra LifeSciences Holdings Corporation has a 52-week low of $37.71 and a 52-week high of $56.42. The firm’s 50 day moving average is $53.59 and its 200-day moving average is $46.59. The stock has a market cap of $3.82 billion, a P/E ratio of 59.67 and a beta of 0.75.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, July 26th. The life sciences company reported $0.45 EPS for the quarter, meeting analysts’ consensus estimates of $0.45. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The firm had revenue of $282.16 million for the quarter, compared to analyst estimates of $283.58 million. During the same period in the prior year, the firm posted $0.40 EPS. The company’s revenue for the quarter was up 13.2% on a year-over-year basis.

In other news, Director Stuart Essig sold 135,000 shares of Integra LifeSciences Holdings Corporation stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $49.90, for a total value of $6,736,500.00. Following the completion of the transaction, the director now directly owns 2,077,475 shares in the company, valued at $103,666,002.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Glenn Coleman sold 13,865 shares of Integra LifeSciences Holdings Corporation stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $45.91, for a total value of $636,542.15. Following the completion of the transaction, the vice president now owns 18,519 shares of the company’s stock, valued at $850,207.29. The disclosure for this sale can be found here. Insiders sold 304,523 shares of company stock valued at $14,812,988 over the last three months. Company insiders own 21.50% of the company’s stock.

Several institutional investors have recently made changes to their positions in IART. BlackRock Inc. boosted its position in shares of Integra LifeSciences Holdings Corporation by 307,726.8% in the first quarter. BlackRock Inc. now owns 7,455,564 shares of the life sciences company’s stock valued at $314,104,000 after buying an additional 7,453,142 shares during the period. Vanguard Group Inc. boosted its position in shares of Integra LifeSciences Holdings Corporation by 116.7% in the first quarter. Vanguard Group Inc. now owns 5,656,048 shares of the life sciences company’s stock valued at $238,289,000 after buying an additional 3,046,488 shares during the period. Champlain Investment Partners LLC boosted its position in shares of Integra LifeSciences Holdings Corporation by 125.2% in the first quarter. Champlain Investment Partners LLC now owns 4,438,760 shares of the life sciences company’s stock valued at $187,005,000 after buying an additional 2,468,145 shares during the period. FMR LLC boosted its position in shares of Integra LifeSciences Holdings Corporation by 44.1% in the first quarter. FMR LLC now owns 7,615,884 shares of the life sciences company’s stock valued at $320,857,000 after buying an additional 2,329,710 shares during the period. Finally, Janus Capital Management LLC boosted its position in shares of Integra LifeSciences Holdings Corporation by 311.6% in the first quarter. Janus Capital Management LLC now owns 2,107,875 shares of the life sciences company’s stock valued at $88,803,000 after buying an additional 1,595,705 shares during the period. Institutional investors own 89.56% of the company’s stock.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Earnings History and Estimates for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply